Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples